Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27.

Zwirner NW, Ziblat A.

Front Immunol. 2017 Jan 19;8:25. doi: 10.3389/fimmu.2017.00025. eCollection 2017. Review.

2.

Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination.

Oth T, Vanderlocht J, Van Elssen CH, Bos GM, Germeraad WT.

Mediators Inflamm. 2016;2016:5740373. doi: 10.1155/2016/5740373. Epub 2016 Feb 11. Review.

3.

Natural killer cells as helper cells in dendritic cell cancer vaccines.

Pampena MB, Levy EM.

Front Immunol. 2015 Jan 28;6:13. doi: 10.3389/fimmu.2015.00013. eCollection 2015. Review.

4.

Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity.

Trivedi S, Jie HB, Ferris RL.

Semin Oncol. 2014 Oct;41(5):678-84. doi: 10.1053/j.seminoncol.2014.08.003. Epub 2014 Aug 12. Review.

5.

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M.

Oncotarget. 2013 Sep;4(9):1527-46.

6.

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Apr 1;19(7):1858-72. doi: 10.1158/1078-0432.CCR-12-2426. Epub 2013 Feb 26.

7.

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.

Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M.

PLoS One. 2012;7(9):e44266. doi: 10.1371/journal.pone.0044266. Epub 2012 Sep 4.

8.

NK cells: key to success of DC-based cancer vaccines?

Lion E, Smits EL, Berneman ZN, Van Tendeloo VF.

Oncologist. 2012;17(10):1256-70. doi: 10.1634/theoncologist.2011-0122. Epub 2012 Aug 20. Review.

9.

Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Van Brussel I, Berneman ZN, Cools N.

Mediators Inflamm. 2012;2012:690643. doi: 10.1155/2012/690643. Epub 2012 Jul 18. Review.

10.

Immunotherapy of cancer in 2012.

Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S.

CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. Review.

11.

Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.

Nguyen-Pham TN, Yang DH, Nguyen TA, Lim MS, Hong CY, Kim MH, Lee HJ, Lee YK, Cho D, Bae SY, Ahn JS, Kim YK, Chung IJ, Kim HJ, Lee JJ.

Cell Mol Immunol. 2012 Jan;9(1):45-53. doi: 10.1038/cmi.2011.23. Epub 2011 Aug 8.

12.

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL.

Immunol Res. 2011 Aug;50(2-3):235-47. doi: 10.1007/s12026-011-8224-z.

13.

Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.

Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P.

J Immunother. 2011 Apr;34(3):270-8. doi: 10.1097/CJI.0b013e31820b370b.

14.

Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen.

Lowe DB, Shearer MH, Aldrich JF, Winn RE, Jumper CA, Kennedy RC.

J Virol. 2010 Oct;84(19):10121-30. doi: 10.1128/JVI.01095-10. Epub 2010 Jul 28.

15.

Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Kalinski P, Okada H.

Semin Immunol. 2010 Jun;22(3):173-82. doi: 10.1016/j.smim.2010.03.002. Epub 2010 Apr 20. Review.

16.

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Pham TN, Hong CY, Min JJ, Rhee JH, Nguyen TA, Park BC, Yang DH, Park YK, Kim HR, Chung IJ, Kim HJ, Lee JJ.

Exp Mol Med. 2010 Jun 30;42(6):407-19.

17.

Integrating costimulatory agonists to optimize immune-based cancer therapies.

Pardee AD, Wesa AK, Storkus WJ.

Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Review.

18.

Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ.

J Immunol. 2009 Dec 1;183(11):7250-8. doi: 10.4049/jimmunol.0901477. Epub 2009 Nov 13.

19.

Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC.

J Virol. 2010 Jan;84(2):883-93. doi: 10.1128/JVI.01512-09. Epub 2009 Nov 4.

20.

Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activation.

Laabs EM, Wu W, Mendez S.

Clin Vaccine Immunol. 2009 Nov;16(11):1601-6. doi: 10.1128/CVI.00249-09. Epub 2009 Sep 23.

Supplemental Content

Support Center